Table 2.
Proportion (95 % CI) of patients treated with placebo from 58 double-blind, placebo-controlled studies performed in patients with schizophrenia spectrum disorder for each outcome measures.
| Number of events | Total number of patient in the placebo arm | PR (%) | 95% CI (%) | Heterogeneity | ||
|---|---|---|---|---|---|---|
| I2 | Cochran's Q test | |||||
| Withdrawal for AEs | 518 | 6097 | 7,2 | (5.9, 8.4) | 84% | <0.001 |
| All AEs | 3621 | 5523 | 66,3 | (62.7, 69.8) | 88% | <0.001 |
| Nervous system disorders | 1596 | 6281 | 27,6 | (22.9, 32.2) | 97% | <0.001 |
| Psychiatric disorders | 1929 | 6298 | 30,4 | (24.8, 36.0) | 98% | <0.001 |
| Gastrointestinal disorders | 693 | 5370 | 12,9 | (10.8, 15.0) | 93% | <0.001 |
AEs, Adverse Events; CI, Confidence Interval; PR, Proportion.